{
}
UBS has reaffirmed its Buy rating for West Pharmaceutical Services, maintaining a price target of $285, citing strong fundamentals and growth potential in the pharmaceutical packaging sector. Despite beating Q4 2024 earnings expectations, the company's stock faced declines due to concerns over future growth and margin pressures. Analysts have mixed views, with KeyBanc lowering its price target to $325 while Evercore ISI initiated coverage with an Outperform rating at $275.
UBS has reiterated a Buy rating for West Pharmaceutical Services, maintaining a price target of $285, citing strong fundamentals and growth potential in the pharmaceutical packaging sector. Despite surpassing Q4 2024 earnings expectations with an EPS of $1.82, concerns over future growth led to a stock decline. The company anticipates 2-3% organic sales growth for 2025 and declared a dividend of $0.21 per share, reflecting its commitment to shareholder value.
UBS has reaffirmed its Buy recommendation for West Pharmaceutical Services, maintaining a price target of $285, following a positive industry expert discussion on growth prospects in pharmaceutical packaging. Despite a strong fourth-quarter performance, the company's shares fell due to concerns over future growth and margin pressures. West Pharma's full-year 2025 EPS guidance is set between $6.00 and $6.20, with anticipated organic sales growth of 2-3%.
UBS analyst Dan Leonard has reiterated a Neutral rating on Mettler-Toledo (NYSE: MTD) with a price target of $1,530.00. The analyst's comments reflect a cautious outlook on the stock's performance moving forward.
UBS has maintained a "Neutral" rating on Qiagen with a price target of $50. The company surpassed expectations for organic growth in the last quarter, and its adjusted operating profit margin was slightly above estimates. However, the growth forecast for the current quarter is below expectations, attributed to a gradual recovery in the consumer goods sector and ongoing investment challenges, though annual targets suggest an acceleration in future quarters.
UBS has upgraded Qiagen to a "Neutral" rating with a target price of $50, following the company's strong organic growth in the last quarter. Analyst Dan Leonard noted that while the adjusted operating profit margin exceeded expectations, the growth forecast for the current quarter is below estimates due to ongoing investment challenges. However, annual targets suggest a potential acceleration in growth in the upcoming quarters.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health's recent partnership with Boehringer Ingelheim and impressive 29.2% revenue growth over the past year further bolster its positive outlook.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health reported a 29.2% revenue increase over the past year and is set to disclose Shield test volumes in its upcoming fourth-quarter results on February 20, 2025.
UBS AG has maintained a "Neutral" rating for Qiagen shares, setting a target price of $50. Analyst Dan Leonard noted mixed signals from the company's quarterly figures and outlook, leading to minor adjustments in his valuation model.As of 13:18 in the XETRA session, Qiagen shares rose 0.3% to €40.89, with a year-to-date increase of 0.7%.
UBS has maintained a 'Neutral' rating for Qiagen, setting a target price of $50. Analyst Dan Leonard noted mixed signals from the company's quarterly results and outlook but made no significant changes to his valuation model.
Dan Leonard
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for west pharma with price target of 285 dollars
16:02 19.03.2025
ubs maintains buy rating for west pharmaceutical with 285 price target
16:02 19.03.2025
ubs maintains buy rating on west pharma with 285 price target
16:02 19.03.2025
ubs maintains neutral rating and price target for metler-toledo
14:37 14.03.2025
UBS maintains neutral stance on Qiagen with 50 dollar price target
08:34 06.02.2025
ubs upgrades qiagen to neutral with target price of 50 dollars
07:34 06.02.2025
ubs names guardant health top pick with maintained price target of 40
22:39 10.01.2025
ubs names guardant health top pick with maintained price target of forty dollars
22:00 10.01.2025
ubs maintains neutral rating on qiagen shares with target price of 50 dollars
13:34 11.11.2024
ubs maintains neutral rating for qiagen with target price of 50 dollars
13:30 11.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Banking Regulations
Global Financial Events
Global Trade Developments
Retail and Consumer Goods
Domestic Politics
CEO Changes
Central Bank Actions
Startups & Entrepreneurship
Market Analysis and Predictions
Workplace Trends
Government Policies
Elections & Campaigns
Government Economic Policies
Inflation and Monetary Impact
Supply Chain Management
Countries:
Companies:
Tesla, Inc.
JPMorgan Chase & Co.
Barclays PLC
Deutsche Bank Money Market PP
Apple Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Credit Suisse Strategic Income I
Lloyds Banking Group plc
BNP Paribas SA
UBS Group AG
The Goldman Sachs Group, Inc.
CREDIT AGRICOLE
Banco Santander, S.A.
Amazon.com, Inc.
SpaceXCoin USD
Credit Agricole
Berkshire Hathaway Inc.
Reinsurance Group of America, Incorporated
Google Inc.
Currencies:
United States Dollar
Euro
Swiss Franc
British Pound Sterling
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Canadian Dollar
Australian Dollar
Offshore Chinese Yuan
Hong Kong Dollar
Singapore Dollar
Mexican Peso
Vietnamese Đồng
Norwegian Krone
Filipino Peso
Indonesian Rupiah
New Zealand Dollar
Thai Baht
People: